Japan· JP-6112400A6019
リンコマイシン塩酸塩水和物
A lincomycin product containing リンコマイシン塩酸塩水和物, registered in Japan, on the national reimbursement list. The same ATC class is registered in 5 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Lincomycin is registered in 5 of 19 countries.
Countries holding a registration under ATC J01FF02 (lincomycin), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 4 of them publish a price we can compare per daily dose
Lincomycin · ATC J01FF02
5 / 19 countries
- Belgiumprice
- Italyprice
- Japan
- Polandprice
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- リンコマイシン塩酸塩水和物
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- J01FF02
- ATC class
- Lincomycin
- Defined daily dose
- 1.8 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
31 interactions on record for lincomycin.
Graded by severity as the source publishes them — 11 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lincomycin · interactions on record
31 records
- 11 moderate
- 20 info
Most severe, free to view
- Sodium picosulfateA06AB08moderate
- KaolinA07BC02moderate
- AttapulgiteA07BC04moderate
- BalsalazideA07EC04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01FF02
Lincomycin, as other registers publish it.
- United StatesLincocinPharmacia & Upjohn Company LLC
- PolandLincocinPfizer Europe MA EEIG
- PolandLincocinDelfarma Sp. z o.o.
- United StatesLincocinPharmacia & Upjohn Company LLC
- PolandLincocinPfizer Europe MA EEIG
- BelgiumLincocin 250 mg/5 mlPfizer
- BelgiumLincocin 300 mg/mlPfizer
- BelgiumLincocin 300 mg/mlPfizer
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d43699e1-787a-422d-8bbf-e7a1fa29dfb2 GET /v1/drugs/d43699e1-787a-422d-8bbf-e7a1fa29dfb2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１．５ｇ５ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "6112400A6019",
"category": "注射薬",
"price_yen": null,
"generic_name": "リンコマイシン塩酸塩水和物",
"product_name_jp": null,
"therapeutic_class": "6112",
"transitional_expiry": null
}See everything about lincomycin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.